Pfizer introduces Zylexis, an immunomodulator for horses

NEW YORK — Pfizer's immunomodulator Zylexis™ is now available in the United States for horses after almost a decade of use and patient data in Germany.

Zylexis prepares the horse's immune system to function more efficiently against equine herpesvirus types 1 and 4 (EHV) and is offered specifically as an aid in reducing upper-respiratory disease caused by these viruses, according to Pfizer.

"Equine herpesvirus is extremely contagious, and a large portion of horses in the U.S. today are already latent carriers of the disease," says Pfizer Senior Veterinarian Dr. Robert Holland. "When they are stressed, these carrier horses may suddenly come down with active disease and show symptoms."

An immunomodulator cannot prevent a horse from contracting a disease, but inactive preparation of Parapox Ovis Virus "can limit the severity and duration of symptoms (of EHV)," Holland says.

For fastest response, call

(800) 366-5288